OA19873A - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof. - Google Patents
2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof. Download PDFInfo
- Publication number
- OA19873A OA19873A OA1202000259 OA19873A OA 19873 A OA19873 A OA 19873A OA 1202000259 OA1202000259 OA 1202000259 OA 19873 A OA19873 A OA 19873A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- pharmaceutically acceptable
- solvaté
- hydrogen
- acceptable sait
- Prior art date
Links
- 101700008359 CDK4 Proteins 0.000 title claims abstract description 31
- 102100019398 CDK4 Human genes 0.000 title claims description 25
- 102100006130 CDK6 Human genes 0.000 title claims description 25
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 title claims description 25
- 230000002401 inhibitory effect Effects 0.000 title abstract description 23
- 239000003112 inhibitor Substances 0.000 title abstract description 15
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract description 12
- 230000001225 therapeutic Effects 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 201000010099 disease Diseases 0.000 claims abstract description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 46
- 239000001257 hydrogen Substances 0.000 claims abstract description 46
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 42
- 108091007476 CDKs Proteins 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 10
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 9
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 9
- 230000001404 mediated Effects 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 230000001808 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000005017 Glioblastoma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010025310 Other lymphomas Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000000240 adjuvant Effects 0.000 claims description 5
- 201000011231 colorectal cancer Diseases 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 abstract description 38
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 abstract description 38
- 239000000651 prodrug Substances 0.000 abstract description 24
- 229940002612 prodrugs Drugs 0.000 abstract description 24
- 239000011780 sodium chloride Substances 0.000 abstract description 13
- 150000003839 salts Chemical class 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 10
- 230000004962 physiological condition Effects 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- -1 5-(piperazin-l-ylmethyl)pyridin2-yl) group Chemical group 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 102000001253 Protein Kinases Human genes 0.000 description 12
- 108091000081 Phosphotransferases Proteins 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 10
- 102000016736 Cyclins Human genes 0.000 description 10
- 108050006400 Cyclins Proteins 0.000 description 10
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102000006313 Cyclin D3 Human genes 0.000 description 8
- 108010058545 Cyclin D3 Proteins 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- WULIZEOAYMSIHS-UHFFFAOYSA-N 4-chloro-5-methylpyrrolo[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C1=NC(Cl)=C2N(C)C(C=O)=CC2=N1 WULIZEOAYMSIHS-UHFFFAOYSA-N 0.000 description 3
- KZSOCAIRCZPXHG-UHFFFAOYSA-N 5-(piperazin-1-ylmethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC=C1CN1CCNCC1 KZSOCAIRCZPXHG-UHFFFAOYSA-N 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 102100010782 EGFR Human genes 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 201000003883 cystic fibrosis Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WGLLSSPDPJPLOR-UHFFFAOYSA-N 2,3-dimethylbut-2-ene Chemical group CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 1
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-Nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- ILYBMUDLGFMEMU-UHFFFAOYSA-N 7-$l^{1}-oxidanyl-2,3,4,5,6,7-hexaoxoheptan-1-olate Chemical compound [O]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C[O-] ILYBMUDLGFMEMU-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 102100013105 CDK1 Human genes 0.000 description 1
- 101700051654 CDK1 Proteins 0.000 description 1
- 102100019396 CDK2 Human genes 0.000 description 1
- 102100019397 CDK3 Human genes 0.000 description 1
- 101700002485 CDK3 Proteins 0.000 description 1
- 102100006116 CDK7 Human genes 0.000 description 1
- 101700007872 CDK7 Proteins 0.000 description 1
- 102100003970 CDK8 Human genes 0.000 description 1
- 102100003972 CDK9 Human genes 0.000 description 1
- 101700049227 CDK9 Proteins 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N CTK1A3526 Chemical group NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025415 Cyclin-Dependent Kinase 8 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229910013131 LiN Inorganic materials 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- STPOIQOOWDHNFI-UHFFFAOYSA-N N=1CN(C=CC=1)C=1C=C2C=NNC2=CC=1 Chemical compound N=1CN(C=CC=1)C=1C=C2C=NNC2=CC=1 STPOIQOOWDHNFI-UHFFFAOYSA-N 0.000 description 1
- HPUYRVXZAIJPKC-UHFFFAOYSA-N N=1NC=C2C=C(C=CC=12)C1=NC(=NC=C1)NC1=NC=C(C=C1)CN1CCNCC1 Chemical group N=1NC=C2C=C(C=CC=12)C1=NC(=NC=C1)NC1=NC=C(C=C1)CN1CCNCC1 HPUYRVXZAIJPKC-UHFFFAOYSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- 108050002653 Retinoblastoma Protein Proteins 0.000 description 1
- 102000012121 Retinoblastoma Protein Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N Tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DLIJPAHLBJIQHE-UHFFFAOYSA-N butylphosphane Chemical compound CCCCP DLIJPAHLBJIQHE-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 150000001354 dialkyl silanes Chemical class 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical class CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 101500002601 human Epidermal growth factor Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical class [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 150000008039 phosphoramides Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical class CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical class O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where R1 is hydrogen, and their prodrugs, where R1 is a metabolizable group under physiological conditions, as cyclindependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
Description
2H-INDAZ0LE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND
THERAPEUTIC USES THEREOF
CROSS-REFERENCE TO RELATED APPLICATION S
This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent
Application No. 62/623,516, fîled on January 29, 2018, the disclosure of which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The présent invention is related to the field of compounds, compositions and methods 10 for the treatment or prévention of a disease, disorder, or medical condition mediated through certain cyclin-dependent kinases (CDKs), especially CDK4 and CDK6. The diseases include various cancers.
BACKGROUND OF THE INVENTION
Cyclin-dependent kinases are a family of protein kinases that regulate cell division 15 and prolifération. Cell cycle progression is controlled by cyclins and their associated cyclindependent kinases, such as CDK1, CDK2, CDK3, CDK4 and CDK6, while other CDKs such as CDK7, CDK8 and CDK9 are critical to transcription. CDK binding to cyclins forms heterodimeric complexes that phosphorylate their substrates on serine and threonine residues, which in turn initiâtes events required for cell-cycle transcription and progression. Since 20 uncontrolled cell prolifération is a hallmark of cancer, and most cancer cells exhibit dcregulation of CDKs, inhibition of CDKs has emerged as a potential treatment for various cancers. Inhibitors with varying degrees of selectivity for CDKs hâve been reported; however, sélective CDK4/6 inhibitors are currently viewed as a promising class of potential anticancer or anti-inflammatory agents due to both the critical rôle of CDK4/6 in regulating 25 cell prolifération and the toxic effects associated with inhibition of other members of the CDK family. ’ ' ' ''
Recently, several types of aminopyrimidine dérivatives'hâve been reported to be sélective CDK4/6 inhibitors. See, e.g.„ WO 2003/062236, WO 20Q7/140222, and US 2010/0160340. Each of these types of molécules contains a 2-aminopyrimidine moiety 30 bound through the 2-amino group to an aryl or heteroaryl ring system. There remains a need ’ to develôp new CDK 4/6 inhibitors as novel anticancer and/or anti-inflammatory agents.
SUMMARY OF THE INVENTION
The présent invention relates to 2-aminopyrimidine-substituted 2H-indazole dérivatives, in which the 2-amino group is substituted by a 5-(piperazin-l-ylmethyl)pyridin2-yl) group, and the 4-N position of the piperazîne moiety is unsubstituted or substituted by a metablizable group that can be hydrolyzed under physiological conditions. These compounds are effective as sélective CDK inhibitors and useful in the treatment or prévention of diseases, disorders, or medical conditions mediated through certain CDKs, in particular CDK4 and CDK6, such as various types of cancers and inflammation-related conditions. The compounds comprising a metabolizable group on the piperazîne moity can serve as more targeted therapeutic agents under controlled release.
One aspect of the présent invention is directed to a compound of formula (I):
I or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, wherein:
R1 is hydrogen or a metabolizable group that can be removed under physiological conditions to form the corresponding unsubstituted compound, wherein the metabolizable group is selected from, but not limited to, -C(O)R, wherein R is H, Ci-Cg alkyl or C3-C7 cycloalkyl, each (except hydrogen) optionally substituted, and -C(O)OR', wherein R' is CjCg alkyl or C3-C7 cycloalkyl each optionally substituted;
R2 is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, and cycloalkylmethyl;
R3 is hydrogen or Ci-Ce alkyl;
R4 is hydrogen, halogen, or Ci-Ce alkyl; and
R5 is hydrogen or halogen.
Another aspect of the présent invention is directed to a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable sait or solvaté thereof, and one or more pharmaceutically acceptable excipients, such as adjuvants, diluents, and/or carriers.
Another aspect of the présent invention is directed to a method of treating a disease, disorder, or condition mediated through at least one of cyclin-dependent kinases (CDK), in particular CDK4, CDK6, or a combination thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable sait or solvaté thereof.
Another aspect of the présent invention is directed to a method of treating a disease, disorder, or condition mediated through at least one of cyclin-dependent kinases (CDK), in particular CDK4, CDK6, or a combination thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable sait or solvaté thereof, and one or more pharmaceutically acceptable excipients, such as adjuvants, diluents, and/or carriers.
In one embodiment, the diseases, disorders, or conditions associated with one or more cyclin-dependent kinases, in particular CDK4, CDK6, or a combination thereof, comprise cancers, which may include, but are not limited to, lung cancer, especially non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, colorectal cancer, glioblastoma, mantel cell lymphoma, chronic myeloid leukemia and acute myeloid leukemia, and complications thereof. In another embodiment, the diseases, disorders, or conditions comprise the inflammation-related diseases and conditions, such as arthritis, e.g., rheumatic arthritis, and cystic fibrosis.
Another aspect of the invention is directed to a method of inhibiting cell prolifération comprising treating the cells with an effective amount of a compound of formula (I), or a sait, solvaté, or composition thereof.
Another aspect of the invention is directed to a method of inhibiting a cyclindependent kinase (CDK), in particular CDK4, CDK6, or a combination thereof, comprising treating the kinase with an effective amount of a compound of formula (I), or a sait, solvaté, or composition thereof.
Another aspect of the présent invention is directed to use of the compounds of this invention for the study of CDKs in biological and pathological phenomena and for comparative évaluation of new kinase inhibitors.
Another aspect of the présent invention is directed to use of a compound of formula (I) according to any embodiments described herein, or a pharmaceutically acceptable sait, solvaté, or composition thereof, in the manufacture of a médicament for treatment of a disease or disorder associated with a CDK activity. The CDK activity is preferably activity of CDK4, CDK6, or a combination thereof.
Still another aspect of the présent invention is directed to the methods of synthesizing the compounds of formula (I) as substantially disclosed and described herein.
Other aspects or advantages of the présent invention will be apparent to those skilled in the art in view of the following detailed description and claims in combination with the knowledge and skills generally known in the field.
DETAILED DESCRIPTION OF THE INVENTION
In a prior patent application the applicant has disclosed a new class of compounds having a core structure of formula (II) containing the piperazine-pyridine-NH-pyrimidineindazole motif, namely the 4-(2H-indazol-5-yl)-N-(5-(piperazin-l-ylmethyl)pyridin-2yl)pyrimidin-2-amine core, useful as CDK, in particular CDK4 and CDK6, inhibitors. See US 2017/0210726, which is incorporated herein by reference in its entirety.
(Π)
Ail the preferred compounds of this class reported previously contain substituents on the indazole and piperazine moieties as shown in formula (I) below. In particular, the nitrogen (N) at position 4 of the piperazine moiety contains a substituent (R1 in formula I) such as C1-C3 alkyl, preferably ethyl group. The présent invention is based on a discovery that the compounds with the piperazine moiety unsubstituted at the 4-position are also active inhibitors of CDK4 and CDK6. This discovery significantly expands the pool of compounds that can serve as potential therapeutic agents for treatment of CDK4 and CDK6 related diseases and disorders, because numerous prodrugs may be designed, including those disclosed in the présent application, that may hâve various advantages in the targeted delivery and/or controlled release.
In one aspect, the présent invention provides a compound of formula (I):
(D or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, wherein:
R1 is hydrogen or a metabolizable group (prodrugs) that can be removed under physiological conditions to form the corresponding unsubstituted compound;
R2 is selected from the group consisting of hydrogen, Ci-Cô alkyl, C3-C6 cycloalkyl, and C3-C6 cycloalkylmethyl;
R3 is hydrogen or Ci-Cô alkyl;
R4 is hydrogen, halogen, or Ci-Ce alkyl; and
R5 is hydrogen or halogen.
In one embodiment of this aspect, R1 is hydrogen.
In another embodiment of this aspect, R1 is a metabolizable group that can be removed under physiological conditions to form the corresponding unsubstituted compound.
In some embodiments, the metabolizable group is RC(O)-, wherein R is Ci-Cg alkyl or C3-C7 cycloalkyl. In some embodiments, R is selected from, but is not limited to, H, methyl, ethyl, propyl, isopropyl, or the like, preferably, methyl or ethyl, and more preferably methyl.
In some embodiments, the metabolizable group is ROC(O)-, wherein R' includes, but 20 is not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, or the like, preferably, methyl or ethyl, and more preferably methyl.
In another embodiment of this aspect, R2 is Ci-Ce alkyl, C3-C6 cycloalkyl, or C3-C6 cycloalkylmethyl.
In another embodiment of this aspect, R2 is methyl, ethyl, propyl, isopropyl, 25 cyclopropyl, cyclopentyl, cyclopropylmethyl, or cyclopentylmethyl.
In another embodiment of this aspect, R3 is Cj-Ce alkyl.
In another embodiment of this aspect, R3 is methyl, ethyl, propyl, or isopropyl.
In certain embodiments, the présent invention provides a compound of formula (I), wherein the R4 substituent is attached at the 7-position of the indazole moiety, characterized by formula (la):
(la) or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, wherein:
R1 is hydrogen or RC(O)-, wherein R is hydrogen or Ci-Ce alkyl;
R2 is selected from the group consisting of hydrogen, Ci-Cô alkyl, C3-C6 cycloalkyl, and cycloalkylmethyl;
R3 is hydrogen or Cj-Cg alkyl;
R4 is hydrogen or halogen; and
R5 is hydrogen or halogen.
In another embodiment of this aspect, R4 is hydrogen or fluoro.
In another embodiment of this aspect, R5 is hydrogen or fluoro.
In another embodiment of this aspect, R1 is hydrogen; R2 is isopropyl, cyclopropyl, cyclopropylmethyl, or cyclopentyl; R3 is methyl or ethyl, R4 is hydrogen or fluoro, and R5 is hydrogen or fluoro.
In certain preferred embodiments of this aspect, the R4 substituent is attached at the 7position of the indazole moiety, and R5 is fluoro, characterized by formula (Ib):
(Ib) wherein R4 is preferably hydrogen or halogen; and when R4 is a halogen, it is preferably chloro (Cl) or fluoro (F), more preferably fluoro (F); and wherein R1, R2, and R3 are each defined in any of the embodiments described here.
In certain preferred embodiments of this aspect, the present invention provides a compound of formula selected from the group consisting of:
(le) or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, wherein R , R , and R are each defined in any of the embodiments described here.
With regard to the compounds of any of formula I, la, Ib, le, Id, or le, the present 10 invention encompasses any and ail possible combinations of the embodiments described herein so long as such combinations would provide stable compounds.
In certain preferred embodiments of this aspect, the present invention provides the compounds listed in Table 1 (infra), and pharmaceutically acceptable salts, solvatés, and prodrugs thereof.
In a preferred embodiment, the present invention provides a compound selected from the group consisting of:
In another aspect, the présent invention provides a pharmaceutical composition comprising a compound of formula (I), (la), (Ib), (le), (Id), or (le) according to any embodiments described here, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, and one or more pharmaceutically acceptable adjuvants, diluents, and/or carriers.
. In another aspect, the présent invention provides a method of treating a disease, disorder, or condition mediated through activity of at least one cyclin-dependent kinase (CDK), comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I), (la), (Ib), (le), (Id), or (le) according to any of the embodiments described herein, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In one embodiment of this aspect, the présent invention provides a method of treating a disease, disorder, or condition mediated through activity of at least one cyclin-dependent kinase (CDK), comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I), (la), (Ib), (le), (Id), or (le) according to any of the embodiments described herein, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, and one or more pharmaceutically acceptable adjuvants, diluents, and/or carriers.
In one preferred embodiment of this aspect, the at least one CDK is CDK4, CDK6, or a combination thereof.
In another preferred embodiment of this aspect, the disease or disorder is a cancer or an inflammation-related disease or condition.
In another preferred embodiment of this aspect, the inflammation-related disease or condition is arthritis, such as rheumatic arthritis, or cystic fibrosis.
In another preferred embodiment of this aspect, the cancer is selected from, but not limited to, colorectal cancer, breast cancer, lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantel cell lymphoma (MCL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and complications thereof.
In another embodiment of this aspect, the compound of the présent invention may be administered to a subject in need thereof in combination with administration of a second therapeutic agent.
In another embodiment, the second therapeutic agent is a different CDK inhibitor, a human epidermal growth factor receptor (e.g., HER2) inhibitor, a serine/threonine kinase inhibitor, such as a mammalian target of rapamycin (mTOR) inhibitor, or an epidermal growth factor receptor (EGFR) inhibitor.
In another aspect, the présent invention provides a method of inhibiting cell prolifération, comprising treating the cells with an effective amount of the compound of formula (I) according to any of the embodiments described, or a sait, solvaté, prodrug, or composition thereof. The method of inhibiting cell prolifération can take place in vivo, e.g., inside the body of a subject, or in vitro, e.g., in a biological sample containing the proliférative cells of a subject.
In a preferred embodiment of this aspect, the proliférative cells are cancer cells, such as, but not limited to, cells of colorectal cancer, breast cancer, lung cancer, especially nonsmall cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantel cell lymphoma (MCL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), or complications thereof.
In another aspect, the présent invention provides a method of inhibiting a cyclindependent kinase (CDK) comprising treating said kinase with an effective amount of a compound of formula (I) according to any embodiments described herein, or a sait, solvaté, prodrug, or composition thereof. The method of inhibiting CDK can take place in vivo, e.g., inside the body of a subject, or in vitro, e.g., in a biological sample containing the proliférative cells of a subject.
In a preferred embodiment of this aspect, the cyclin-dependent kinase is CDK4,
CDK6, or a combination thereof.
In another aspect, the présent invention provides use of a compound of formula (I), (la), (Ib), (le), (Id), or (le) according to any embodiments described herein, or a pharmaceutically acceptable sait, solvaté, prodrug, or composition thereof, in the manufacture of a médicament for treatment of a disease or disorder associated with a CDK activity. The
CDK activity is preferably activity of CDK4, CDK6, or a combination thereof.
In one embodiment of this aspect, the disease or disorder is selected from the group consisting of colorectal cancer, breast cancer, lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantel cell lymphoma (MCL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML).
In another embodiment of this aspect, the disease or disorder is an inflammationrelated disease or condition, such as arthritis, in particular rheumatic arthritis, or cystic fibrosis.
In another aspect, the présent invention provides a method of preparing compounds of formula (I), comprising a step of coupling intermediate E with intermediate G:
wherein R1 is RC(O)- or RO(CO)-; and wherein R, R', and R2 through R5 are defined according to any of the embodiments described herein, and X is Cl, Br, or I.
When R1 is hydrogen, it can be formed by base or acid catalyzed hydrolysis of the intermediate (M), where Rp is a protecting group.
(M)
When Rp is a protecting group, the method further comprises removal of Rp through base and/or acid mediated hydrolysis (for example, removal of t-Boc group with HCl) to form the compound of formula (laa):
(M) (laa)
In a preferred embodiment, Rp is t-BuOC(O)- (“t-Boc”), which can be readily removed by acid catalyzed hydrolysis to form the corresponding unsubstituted compound where R1 is hydrogen.
The prodrugs disclosed herein can be optionally prepared through a reaction of the 5 compound of formula (laa) with an acylating agent R*X4 to form R1, wherein R1 is RC(O)or ROC(O)-, and X4 is Cl or Br, or the corresponding anhydride (RCO)2O.
laa I
In one embodiment of this aspect, the method further includes the steps of converting intermediate C to intermediate D and coupling the intermediate D with a pyrimidine compound H to form the intermediate E:
x2
CD E wherein Rx and Ry are independent alkyl, aryl, cycloalkyl, or alternatively together 15 form an alkylene group, each optionally substituted by one or more substituents independently selected from C1-C4 alkyl, halogen or phenyl; and wherein X , X , and X are each independently Cl, Br, or I, on condition that the intermediate D couples with the compound H selectively at the X2 site over the X3 site, preferably having a higher than 90:10 selectivity, more preferably having a 95:5 selectivity, and most preferably exclusively at the 20 X2 site.
In one spécifie embodiment, boronation is realized through reaction of a bromide intermediate C (where X1 is Br) with bis(pinacolato)diboron (B2pin2) in the presence of a catalyst, e.g., Pd(dppf)C12, to form the 5-(pinacolato)boron-substituted 2H-indazole intermediate D, where Rx and Ry together form 1,1,2,2-tetramethyl-ethylene group. The intermediate D then reacts with compound 5-fluoro-2,4-dichloropyrimidine (H, where R5 is fluoro, and both X2 and X3 are chloro) to form the desired 5-(pyrimidin-4-yl)-substituted 2Hindazole intermediate E (R5 is F and X3 is Cl).
In one embodiment of this aspect, the method further includes the steps of converting an ortho-nitrobenzaldehyde starting material SI to intermediate A through phosphinemediated condensation/cyclization and converting the intermediate A to the intermediate C through deprotonation and alkylation at the 3-position ofthe 2H-indazole intermediate A:
SI AC wherein X1 is Cl, Br, I, or MeSO3-; and wherein R2 and R3 are as defined according to any of the embodiments described herein.
In another embodiment of this aspect, alternatively, converting the intermediate A to the intermediate C comprises converting the intermediate A to an alcohol intermediate B followed by réduction of the alcohol intermediate B to form the intermediate C:
(aldéhyde or ketone)
A B C wherein R2a and R2b are each independently hydrogen, alkyl, cycloalkyl, or together
I vvw^ form an alkylene group so that the group R2a R2b formed in the intermediate C is R2 as defined according to any ofthe embodiments described herein. This approach is particularly convenient for préparation of intermediate C where R2 is ethyl, propyl, isopropyl, iso-butyl, cycloalkyl, cycloalkylmethyl, or the like, by using the corresponding aldéhyde or ketone as the alkylating agent or solvent.
In one embodiment of this aspect, the method further includes a step of forming the intermediate G through coupling the pyridine aldéhyde compound S2 and the piperazine compound S3 to form an intermediate F, followed by converting the intermediate F to the intermediate G:
S2 S3 F G wherein Rp is a protecting group or R1, where R1 is RC(O)- or ROC(O)-; X4 is selected from the group consisting of Cl, Br, I, and -NO2; and wherein said converting the intermediate F to the intermediate G comprises replacing X4 with NH2 when X4 is Cl, Br, or I; or alternatively reducing the nitro group (-NO2) to amino group (-NH2) when X4 is -NO2.
Compounds provided by this invention are also useful for the study of kinases in biological and pathological phenomena, the study of transduction pathways mediated by such kinases, and the comparative évaluation of new kinase inhibitors.
Unless otherwise indicated, the term “alkyl,” as used herein, is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups containing 1 to 8 carbons, preferably 1 to 6, more preferably 1 to 4, carbons. The term encompasses, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, or the like.
Unless otherwise indicated, the term “alkylene,” as used herein, refers to a bivalent saturated aliphatic radical derived from an alkane by removal of two hydrogen atoms. Examples include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), or the like.
Unless otherwise indicated, the term “cycloalkyl”, as used herein alone or as a part of another group, includes saturated cyclic hydrocarbon radical having 3 to 8 carbons forming the ring. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
Unless otherwise indicated, the term “aryl”, as used herein alone or as part of another group, refers to monocyclic or bicyclic aromatic radical containing 6 to 10 carbons in the ring portion (such as phenyl and naphthyl, including 1-naphthyl and 2-naphthyl).
“Halo” or “halogen” as used herein, refers to fluoro (F), chloro (Cl), bromo (Br), and iodo (I).
Further, the alkyl, alkylene, cycloalkyl, and cycloalkylmethyl groups optionally can be independently further substituted with one or more, preferably 1 to 3, substituents independently selected from the group consisting of halogen and C1-C4 alkyl.
The compounds of the présent invention are generally recognized as organic bases, which are able to react with acids, specifically pharmaceutically acceptable acids, to form pharmaceutically acceptable salts.
As used herein, the term pharmaceutically acceptable sait refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animais without undue toxicity, irritation, allergie response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. See, e.g., S. M. Berge et al., J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycérophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stéarate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Preferred pharmaceutically acceptable salts include the hydrochloride salts.
The term “solvaté,” as used herein, means a physical association of a compound of this invention with a stoichiometric or non-stoichiometric amount of solvent molécules. For example, one molécule of the compound associâtes with one or more, preferably one to three, solvent molécules. It is also possible that multiple (e.g., 1.5 or 2) molécules of the compound share one solvent molécule. This physical association may include hydrogen bonding. In certain instances the solvatés will be capable of isolation as crystalline solid. The solvent molécules in the solvaté may be présent in a regular arrangement and/or a non-ordered arrangement. Exemplary solvatés include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
Although the compounds of general formula (I) disclosed herein may be in the “prodrug” forms themselves, i.e., when R1 is an acyl (i.e., RC(O)-) or ester (i.e., ROC(O)-) group, these “prodrugs” may be generated in vivo under physiological conditions from other “prodrugs”. Thus, for these compounds disclosed, the term “prodrug,” as used herein, refers to a dérivative of a compound that can be transformed in vivo to yield the parent compound, for example, by hydrolysis in blood. Common examples of prodrugs in the présent invention include, but are not limited to, amide or phosphoramide forms of an active amine compound, for example, the compound of formula (II):
(Π) wherein R6 is an acyl group (e.g., acetyl, propionyl, formyl, etc.) or phosphoryl [e.g., P(=O)(OH)2] group; or alternatively, when R3 in an active compound is hydrogen, the corresponding amide or phosphoramide compounds may serve as prodrugs. Such amide or phosphoramide prodrug compounds may be prepared according to conventional methods as known in the art.
When it is possible that, for use in therapy, therapeutically effective amounts of a compound of the présent invention, or pharmaceutically acceptable salts or solvatés thereof, may be administered as the raw Chemical, it is possible to présent the active ingrédient as a pharmaceutical composition. Accordingly, the disclosure further provides pharmaceutical compositions, which include any compounds of the présent invention, or pharmaceutically acceptable salts or solvatés thereof, and one or more, preferably one to three, pharmaceutically acceptable carriers, diluents, or other excipients. The carrier(s), diluent(s), or other excipient(s) must be acceptable in the sense of being compatible with the other ingrédients of the formulation and not deleterious to the subject being treated.
The term “pharmaceutically acceptable,” as used herein, refers to the property of those compounds, materials, compositions, and/or dosage forms which are, within the scope of Sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergie response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingrédient per unit dose. Typically, the pharmaceutical compositions of this disclosure will be administered from once every 1 to 5 days to about 1 -5 times per day, or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingrédient that may be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of administration, the rate of excrétion of the compound employed, the duration of treatment, and the âge, gender, weight, and condition of the patient. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingrédient. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small incréments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford effective results without causing substantial harmful or deleterious side effects.
When the compositions of this disclosure comprise a combination of a compound of the présent disclosure and one or more, preferably one or two, additional therapeutic or prophylactic agent, both the compound and the additional agent are usually présent at dosage levels of between about 10 to 150%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
Pharmaceutical formulations may be adapted for administration by any appropriate route, for example, by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parentéral (including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial, intrastemal, intrathecal, intralesional, intravenous, or intradermal injections or infusions) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingrédient with the carrier(s) or excipient(s). Oral administration or administration by injection are preferred.
Pharmaceutical formulations adapted for oral administration may be presented as discrète units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid émulsions or water-in-oil émulsions.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as éthanol, glycerol, water, and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent can also be présent.
Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloïdal silica, talc, magnésium stéarate, calcium stéarate, or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the médicament when the capsule is ingested.
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like. Lubricants used in these dosage forms include sodium oleate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, betonite, xanthan gum, and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant, and pressing into tablets. A powder mixture is prepared by mixing the compound, suitable comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelating, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a résorption accelerator such as a quatemary sait and/or and absorption agent such as betonite, kaolin, or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the resuit is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stéarate sait, talc, or minerai oil. The lubricated mixture is then compressed into tablets. The compounds of the présent disclosure can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating of wax can be provided.
Dyestuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as solution, syrups, and élixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while élixirs are prepared through the use of a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, fiavor additive such as peppermint oil or natural sweeteners, or saccharin or other artificial sweeteners, and the like can also be added.
Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release, for example, by coating or embedding particulate material in polymers, wax, or the like.
It should be understood that in addition to the ingrédients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
The term “subject” or patient includes both humans and other mammalian animais, preferably humans.
The term “therapeutically effective amount refers to an amount of a compound or composition that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. A therapeutically effective amount can vary depending on, inter alia, the compound, the disease and its severity, and the âge, weight, or other factors of the subject to be treated. When applied to an individual active ingrédient, administered alone, the term refers to that ingrédient alone. When applied to a combination, the term refers to combined amounts of the active ingrédients that resuit in the therapeutic effect, whether administered in combination, serially, or simultaneously.
In some embodiments, the term treating or “treatment” refers to inhibiting the disease, disorder, or condition, i.e., arresting its development; or relieving the disease, disorder, or condition, i.e., causing régression of the disease, disorder, and/or condition. Thus, in some embodiments, “treating or treatment refers to ameliorating a disease or disorder, which may include ameliorating one or more physical parameters, though maybe indiscemible by the subject being treated. In some embodiments, treating or treatment includes modulating the disease or disorder, either physically (e.g., stabilization of a discemible symptom) or physiologically (e.g., stabilization of a physical parameter) or both.
In yet some embodiments, treating or treatment includes delaying the onset of the disease or disorder.
METHODS
Abbreviations
The following abbreviations may be used in this application:
B2pin2 = bis(pinacolato)diboron
MeOH = methanol
LDA = lithium diisopropylamide
LiHMDS = lithium bis(trimethylsilyl)amide [LiN(SiMe3)2]
Pd(dppf)C12 = [l,l'-bis(diphenylphosphino)fenOcene]dichIoropalladium(II)
Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(0)
Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene nBujP = tri-n-butylphosphine
DCM = dichloromethane
THF = tetrahydrofuran;
DIEA = DIPEA = diisopropylethylamine;
sat. = saturated aqueous solution;
aq. = aqueous
FCC = flash column chromatography using silica;
TFA = trifluoroacetic acid;
r.t. = room température;
DMF = NtiV-dimethylformamide;
DMSO = dimethylsulfoxide;
DMA = A^V-dimethylacetamide;
EtOAc = ethyl acetate;
h = hour(s).
Chemical Synthesis
Synthesis of Compounds of Formula (I)
The synthesis of compounds of formula (I) is exemplified in the General Synthetic
Schemes 1-4:
1. Synthesis of the indazole intermediate C (Scheme 1)
A suitable 5-halo-2-nitrobenzaldehyde starting material SI (X1 = Cl, Br, or I) is allowed to react with a primary amine (R3NH2) in the presence of a phosphine, e.g., tri19 butylphosphine, to form the indazole dérivative A (Genung, N. E. et al. Org. Lett. 2014 16, 3114-3117), which in turn is deprotonated at the 3-position using a strong base, e.g., LDA, followed by reaction with an alkylation reagent R2X (X= e.g., Cl, Br, I, or methanesulfonate) to form the intermediate C with the desired R2, R3, and R4 in place. Alternatively, the deprotonated compound A can be allowed to react with an aldéhyde or ketone to form an alcohol adduct, which is reduced (e.g., by a dialkylsilane) to form the desired intermediate C.
Scheme 1
2. Synthesis of the pyrimidine-substituted 2H-indazole intermediate E (Scheme 2)
The intermediate C is allowed to undergo a boronation reaction in the presence of a catalyst (e.g., a palladium catalyst) to form the boronate intermediate D, which is allowed to couple with a halogen-substituted pyrimidine dérivative H to form a 5-(pyrimidin-3-yl)indazole intermediate E.
Scheme 2
3. Synthesis of the 2-amino-5-piperazinylmethyl-pyridine intermediate G (Scheme 3(a) and 3(b))
A 6-halogen or 6-nitro substituted pyridine-3-carbaldehyde starting material S2 and a l-R’-substituted (where R1 is not hydrogen) or l-Rp-substituted piperazine starting material S3 are allowed to undergo a reductive amination reaction to form a 2-amino-5piperazinylmethyl-pyridine intermediate F, which is in tum converted to the 2-amino-5piperazinylmethyl-pyridine intermediate G through substitution of the halogen or réduction of nitro group on the pyridine ring.
Scheme 3 (a)
(b)
4. Synthesis of compounds of formula (I) (Scheme 4(a) and 4(b))
Coupling of the pyrimidine-substituted 2H-indazole intermediate E with the 2-amino5-piperazinemethyl-pyridine intermediate G in the presence of a catalyst (e.g., palladium catalyst) provides the compound of formula (I), where R1 is not hydrogen. Alternatively, coupling of the 2H-indazole intermediate E with an Rp-substituted intermediate G forms an intermediate (M), followed by removal of the protecting group Rp to form the compound of formula (I), where R1 is hydrogen. The latter can also be further converted to other compounds of formula (I), wherein R1 is not hydrogen, by reacting with an acylating agent. Scheme 4 (a)
EXAMPLES
The following non-limiting Examples further illustrate certain aspects of the présent invention. These compounds are prepared according to the general Synthetic Schemes described above.
5-FIuoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)-N-(5-(piperazin-l-methyl)pyridin-2yI)pyrimidin-2-amine hydrochloride (LHC!)
Compound 1 was prepared using Scheme 5 below, and the experimental details are further described for illustration purpose.
Scheme 5
Me
Br
B2pin2
Pd(dppf)CI2
KOAc; dioxane/H2O 90’C
Pd2(dba)3
Me
Xantphos;
Cs2CO3; dioxane; 110°C
Z-Butyl 4-((6-bromopyridin-3-yl)methyl)piperazine-l-carboxylate (iii)
A solution of 5-bromopyridine-2-carbaldehyde (i; 71.4 g, 384 mmol, 1 equiv), 1-Bocpiperzine (ii; 72.8 g, 391 mmol, 1.02 equiv), dichloromethane (1.2 L), and acetic acid (2.4 mL) was cooled to 15 °C and sodium triacetoxyborohydride (164.9 g, 777.8 mmol, 2.03 equiv) was added portionwise to the mixture at 25 °C. The resulting solution was stirred for 24 h at room température. An additional portion of sodium triacetoxyborohydride (13 g, 61.3 mmol, 0.16 equiv) was added portionwise at 15 °C. The reaction was then quenched with aq 2N NaOH (250 mL) and the resulting solution was stirred for another 0.5 h. The organic layer was washed twice with water, dried and concentrated. The residue was recrystallized with 4:1 petroleum ether/ethyl acetate to yield 107.7 g (78% yield) of iii as a light yellow solid.
r-Butyl 4-((6-aminopyridîn-3-yl)methyl)piperazine-l-carboxylate (iv)
A solution of intermediate iii (100 g, 281 mmol, 1 equiv), CU2O (20 g 140 mmol, 0.5 equiv), and aq ΝΗ3Ή2Ο (250 mL, 2.5 equiv) was stirred for 8 h at 120° C (16 Mpa) in a 500 mL autoclave. The solution was cooled to room température then quenched with aq 2N NaOH solution (1 L) and extracted twice with CH2CI2. The organic phase was washed with 15 L of brine, then dried and concentrated. Purification by column chromatography (50:1 to 10:1 CH2Cl2/MeOH on silica gel) resulted in 25.4 g (31% yield) of iv as an off-white solid.
5-(2-Chloro-5-fluoropyrimidin-4-yl)-3-isopropyl-2-methyl-2H-indazoIe (vii)
A solution of 5-bromo-3-isopropyl-2-methyl-2/7-indazole (v; 30 g, 118 mmol, 1 equiv), 4,4,5,5-tetramethyl-2-(tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (36.1 g, 142 mmol, 1.2 equiv), KOAc (23.3g, 237.8 mmol, 2 equiv), in DMF (150 mL) was degassed. Pd(dppf)C12 (2.6 g, 0.01 equiv) was added and the reaction mixture was stirred under a N2 atmosphère for 8 h at 90-100 °C, cooled to 30-40 °C and then diluted with 300 mL of water. The mixture was stirred for 1-2 h at 0-10 °C and the product was collected by filtration. The filter cake was washed with water to afford 3-isopropyl-2-methyl-5-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-2//-indazole (vi). which was used directly in the next step.
A degassed mixture of intermediate vi (1 equiv), 2,4-dichloro-5-fluoropyrimidine (23.75 g, 180 mmol, 1.2 equiv), K2CO3 (32.76 g, 237 mmol, 1.3 equiv), Pd(dppf)Cl2 (0.87 g,0.03 equiv), 1,4-dioxane (300 mL), and water (60 mL, 2 equiv) was stirred for 5-8 h at 8595 °C under a N2 atmosphère. After cooling to 30-40 °C, the reaction mixture was filtered and the filtrate was partially concentrated in vacuo and then added slowly to 300 mL of water. The resulting mixture was extracted with dichloromethane and the organic phase was washed with water, dried, concentrated and purified by column chromatography (50:1 to 10:1 CH2Cl2/MeOH on silica gel) to yield 14.8 g (40% yield) of vii as of an off white solid. ’H NMR (300 MHz, CDC13, 5): 1.58 (d, 6H), 3.48-3.57 (m, 1H), 4.19 (s, 3H), 7.24 (d,lH), 8.038.07 (m, 1H), 8.47 (d, 1H), 8.68 (s, 1H); LC-MS (ES+) m/z: 305 (M+H)+.
/-Butyl-4-((6-((5-fluoro-4-(3-isopropyl-2-methyI-2H-indazol-5-yl)pyrimidin-2yl)amino)pyridin-3-yl)methyl)piperazine-l-carboxylate (viii)
A mixture of vii (14.8 g, 484 mmol, 1.0 equiv), iv (16.3 g, 557 mmol, 1.15 equiv), K3PO4-3H2O (25.8 g, 967 mmol, 2.0 equiv), Pd(dba)3 (1.3 g, 1.5 mmol, 0.03 equiv) and Xantphos (0.8 g, 1.5 mmol, 0.03 equiv) in 150 mL of 1,4-dioxane was degassed withN2, then heated while stirring at 90-100 °C for 24 h. Additional Pd(dba)3 (0.42 g, 0.72 mmol, 0.015 equiv) and Xantphos (0.42 g, 0.72 mmol, 0.015 equiv) were added and heating at 90-100 °C with stirring was continued for 8 h. The reaction mixture was cooled to 40-50 °C, added to ice-water (300 mL), stirred for 3-5 h and extracted with dichloromethane. The organic phase was washed with water, dried and concentrated in vacuo. Purification by column chromatography (50:1 to 10:1 CH2Cl2/MeOH on silica gel) provided 22.8 g (84% yield) of viii as an off-white solid.
5-Fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)-N-(5-(piperazin-l-yImethyl)pyridin2-yl)pyrimidin-2-amine hydrochloride (1*HCI)
A solution of viii (25.1 g, 604 mmol, 1.0 equiv) in a mixture of HCl (g) in ethyl acetate/methanol (500 mL) was stirred at room température for 24 h. The solution was concentrated to yield 29.8 g (99% yield) of 1*HC1 as an off-white solid. 'HNMR (300 MHz,
D20, δ): 1.44 (d, 6 H, J= Ί Hz), 3.44-3.56 (overlapping m, 9H), 4.06 (s, 3H), 4.32 (s, 2H),
7.43 (d, 1H, J = ΊΑ), 7.55 (d, 1H, J= 7.6), 8.00-8.63 (m, 5H) ppm.; LC-MS (ES+) m/z: 461 (M+H)+.
The free base form of 1 can be formed by standard techniques that employ appropriate 5 bases such as NaOH, Na2CO3, etc.
Compounds 1 and other selected examples (Compounds 2-36) of the présent invention are listed in Table 1, ail of which are or can be prepared according to the methods described herein.
Table 1. Selected examples of the compounds of formula (I)
Example | Structure | Name |
1 | jCTWX. H L JL y— n Me—γ Me Me | 5-fiuoro-4-(3-isopropyl-2methyl-2H-indazol-5-yl)-N(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
2 | H N ΎΎ /- N Me—( Me Me | 5-fluoro-4-(7-fluoro-3 isopropyl-2-methyl-2Hindazol-5-yl)-N-(5(piperazin-1ylmethyl)pyridin-2yl)pyrimidin-2-amine |
3 | I 0 i IZ \ fl J <0 \ | 4-(3-cyclopentyl-2-methyl2H-indazoI-5-yl)-5-fluoroN-(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
4 | hn. J /L- JL /F H L JL y- n /—( Me | 4-(3-cyclopentyl-7-fluoro-2methyl-2H-indazol-5-yl)-5fluoro-N-(5 -(piperazin-1 ylmethyl)pyridin-2yl)pyrimidin-2-amine |
5 | H IL Λ V” / N Me—ç Me Me | 4-(7-fluoro-3-isopropyl-2methyl-2H-indazol-5-yl)-N(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
6 | Φ u. 2 ,S ZI 0 0 X | 4-(3-cyclopentyl-7-fluoro-2methyl-2H-indazol-5-yl)-N(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
7 | I 0 d ΙΖ ΰ LXP* Φ | 4-(3-cyclopropyl-2-methyl2H-indazol-5-yl)-5-fluoroN-(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
8 | <D tL 2 .2 W Î u. Q ZI ? X | 4-(3-cyclopropyl-7-fluoro2-methyl-2H-indazol-5-yl)5-fluoro-N-(5-(piperazin-1 ylmethyl)pyridin-2yl)pyrimidin-2-amine |
9 | Φ z Σ u. 1 ] Q zx P 5 | 4-(3-cyclohexyl-2-methyl2H-indazol-5-yl)-5-fluoroN-(5-(piperazin-1 ylmethyl)pyridin-2yl)pyrimidin-2-amine |
10 | WiC, H IL A / N /—\ Me | 4-(3-cyclohexyl-7-fluoro-2methyl-2H-indazol-5-y 1)-5 fluoro-N-(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
11 | N^YF κίγ LÀnYA^ η LÀ / N Et Me | 4-(3-ethyl-2-methyl-2Hindazol-5-yl)-5-fluoro-N-(5(piperazin-1ylmethyl)pyridin-2yl)pyrimidin-2-amine |
12 | I 0 i ZZ zH 1 ?=< m ,zY ' 2 Z (S | 4-(3 -(sec-butyl)-7 -fluoro-2methyl-2H-indazol-5-yl)-5fluoro-N-(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
13 | T 0 d IZ zK / /=\ Ή ^~Z m | 4-(2-ethyl-3 -isopropyl-2Hindazol-5-yl)-5-fluoro-N-(5(piperazin-1ylmethyl)pyridin-2yl)pyrimidin-2-amine |
14 | z 0 à zz ZH /=\ H ( m -n r* | 4-(3-cyclopropyl-2-ethyl-7fluoro-2H-indazol-5-yl)-5fluoro-N-(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
15 | Z Q d zz zK 1 Y* CD | 4-(3-(cyclopropylmethyl)-2methyl-2H-indazol-5 -yl)-5 fluoro-N-(5-(piperazin-lylmethyl)pyridin-2yl)pyrimidin-2-amine |
16 | VOYY s Y /-N Me—( Me Me | 1 -(4-((6-((5-fluoro-4-(3isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazin-1 yl)ethan-l-one |
17 | » Η V Me—ζ Me Me | 1-(4-((6-((5-fluoro-4-(7fluoro-3-isopropyl-2methyl-2H-indazol-5yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazin-l yl)ethan-l-one |
18 | ï - v, /- N Z^| Me | 1 -(4-((6-((4-(3-cyclopentyl2-methyl-2H-indazol-5 -y 1)5-fluoropyrimidin-2yl)amino)pyridin-3yl)methyl)piperazin-l yl)ethan-l-one |
19 | νΟηχχΥ s - u / N /--/ Me | 1 -(4-((6-((4-(3-cyclopentyl7 -fluoro-2-methyl-2Hindazol-5-yl)-5fluoropyrimidin-2yl)amino)pyridin-3yl)methyl)piperazin-l yl)ethan-l-one |
20 | ΎΟΧΧΧΧν S - χχ /-N Me-γ Me Me | l-(4-((6-((4-(7-fluoro-3isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazin-l yl)ethan-l-one |
21 | Y^N'^rj^N S H Un V n / N </ Me | 1 -(4-((6-((4-(3-cyclopropyl2-methyl-2H-indazol-5-yl)5-fluoropyrimidm-2yl)amino)pyridin-3yl)methyl)piperazin-1 yl)ethan-l-one |
22 | v«j Vxnanx^ f S H La v / N /—\ Me | 1 -(4-((6-((4-(3-cyclohexyl7-fluoro-2-methyl-2Hindazol-5-yl)-5fluoropyrimidin-2yl)amino)pyridin-3yl)methyl)piperazin-l yl)ethan-l-one |
23 | φ ζ * // \ ^-1 ® \ / ν'2 LL /=/ 1 \ / Φ Q ζχ ο ο χ | 4-((6-((5-fluoro-4-(3isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-1 carbaldehyde |
24 | vOXuXv Ϊ - u / Ν Me—ζ Me Me | 4-((6-((5-fluoro-4-(7-fluoro3-isopropyI-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carbaldehyde |
25 | ° Η Μν W t4 3 >Ν Me—ζ Me Me | 4-((6-((4-(7-fluoro-3isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2- yl)amino)pyridin-3 yl)methyl)piperazine-l carbaldehyde |
26 | Φ κχ2 U. \=/ 1 \ Q ΖΧ ? Ρ, χ | 4-((6-((4-(3-cyclopentyl-2methyl-2H-indazol-5-yl)-5fIuoropyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carbaldehyde |
27 | φ Ζ-2 2 Λ Q ζχ Ρ Ρ. X | 4-((6-((4-(3-(sec-butyl)-2methyl-2H-indazol-5-yl)-5fluoropyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-lcarbaldehyde |
28 | ΗΥΝ^ Ο Η Ο /\ /-Ν Me | 4-((6-((4-(3(cyclopropylmethyl)-2methyl-2H-indazol-5-yl)-5fluoropyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-1 carbaldehyde |
29 | Meo O JJ J H O / N Me—( Me Me | methyl 4-((6-((5 -fluoro-4(3-isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carboxylate |
30 | 2 φ O °=< 0 d IZ J s yj φ / \ / λΤ ή sJJ d φ r \ // 2 Ή Φ | methyl 4-((6-((5 -fluoro-4(7-fluoro-3-isopropyl-2methyl-2H-indazol-5yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carboxylate |
31 | ° H u» Y N /-N Me J Me Me | ethyl 4-((6-((5-fluoro-4-(3isopropyl-2-methyl-2Hindazol-5 -yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carboxylate |
32 | m δ °=( 0 d IZ J y=< ® / \ 1 /=\ H S-J V \ s-z'zJ Φ | ethyl 4-((6-((5-fluoro-4-(7fluoro-3 -isopropyl-2methyl-2H-indazol-5 yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-1 carboxylate |
33 | •^O ^O'nXXptf ï - V» / N Me—/ Me Me | methyl 4-((6-((4-(7-fluoro3-isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)ammo)pyridin-3yl)methyl)piperazine-1 carboxylate |
34 | .VOOXC S H Un Y N /-N Me~T Me Me | /er/-butyl 4-((6-((5-fluoro-4(3-isopropyl-2-methyl-2Hindazol-5-yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carboxylate |
35 | CD C O °=< O d IZ s 5=( ® / \ 1 /=\ F <0 \ \___// 2·Ζ'Ζ T Φ | tert-butyl 4-((6-((5-fluoro-4(7-fluoro-3-isopropyl-2methyl-2H-indazol-5yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carboxylate |
36 | ω Wt'2 /7 \ Φ \ / / Φ Q ' ZI « o 3 m | tert-butyl 4-((6-((4-(7fluoro-3-isopropyl-2methyl-2H-indazol-5yl)pyrimidin-2yl)amino)pyridin-3yl)methyl)piperazine-l carboxylate |
BIOLOGICAL ASSAYS
Compounds of the formula (I) are novel CDK4/6 inhibitors that hâve been or can be evaluated for their activity according to the procedures described below, using compound 1*HC1 to illustrate.
CDK4/cyclin Dl, CDK4/cyclin D3, CDK6/cyclin Dl, and CDK6/cyclin D3 were added to freshly prepared substrate solution (RB Protein, 3 μΜ) which was in freshly made reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCh, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO) and gently mixed, respectively. Compound 1-HC1 was tested in a 10-dose IC5o mode with 3-fold dilution starting at 0.1 μΜ. Compound 1-HC1 was prepared and diluted in DMSO and was delivered into the kinases/substrate reaction mixture by Acoustic technology (Echo550; nanoliter range), then incubated for 20 min at room température. Then 33P-ATP (1 μΜ) was added into the reaction mixture to initiate the reaction. The kinase reaction was incubated at room température for 2 hours. The reactions were spotted onto P81 ion-exchange paper and radioactivity was detected by filter-binding method. The kinase activity data were expressed as the percent remaining kinase activity in test samples compared to vehicle (Dimethyl Sulfoxide) reactions. The compound’s IC50 values and curve fits for each kinase were obtained by fitting to a nonlinear régression curve with the “four parameter logistic équation” in Prism (GraphPad Softwere). Under the conditions, IC50 values for 1HC1 were determined for ail 4 kinases: CDK4/cyclin Dl, CDK4/cyclin D3, CDK6/cyclin Dl, and CDK6/cyclin D3 and are shown in Table 2, as compared with those of ethylated counterpart, namely N-(5-((4ethylpiperazin-l-yl)methyl)pyridin-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-531 yl)pyrimidin-2-amine, or compound 37. The results are comparable with, or in certain cases better than, those of compound 37. The significance of this discovery is that in principal compound 1 can be administered through various prodrug forms disclosed herein, which can be hydrolyzed under physiological conditions to generate active compound 1 in situ, in which 1 serves as a common active moiety, thus achieving controlled release for better targeting the diseases, in particular tumors.
Table 2. IC50 values of compounds 1-HC1 and 37 for CDK4/cyclin Di, CDK4/cyclin D3, CDK6/cyclin Di, and CDK6/cyclin D3.
Kinases | Compounds (IC50, M) | |
1 · HCl | 37 | |
CDK4/cyclin DI | 7.05E-10 | 1.47E-09 |
CDK4/cyclin D3 | 3.99E-09 | 1.98E-09 |
CDK6/cyclin DI | 1.11E-09 | 2.38E-08 |
CDK6/cyclin D3 | 2.56E-08 | 5.66E-09 |
It will be understood by those of skill in the art that numerous and various modifications can be made to the compounds, compositions, and/or methods of the présent invention without departing from the spirit of the invention. Therefore, the various embodiments of the présent invention described herein are illustrative only, and are not intended to limit the scope of the invention in any way. Ail référencés cited herein are incorporated by reference in their entirety.
Claims (19)
- What is claimed is:1. A compound of formula (I):(I) or a pharmaceutically acceptable sait or solvaté thereof, wherein:R1 is hydrogen, -C(O)R, or-C(O)OR', wherein R is hydrogen, Ci-Cg alkyl, or C3-C7 cycloalkyl; and wherein R' is Ci-Cg alkyl or C3-C7 cycloalkylR2 and R3 are each independently hydrogen, Ci-Cg alkyl, C3-C7 cycloalkyl, or C3-C7 cycloalkylmethyl;R4 is hydrogen, halogen, Ci-Cg alkyl, or C3-C7 cycloalkyl; andR5 is hydrogen or halogen.
- 2. The compound of claim 1, or a pharmaceutically acceptable sait or solvaté thereof, wherein R1 is hydrogen.
- 3. The compound of claim 1, or a pharmaceutically acceptable sait or solvaté thereof, wherein R1 is -C(O)R, wherein R is Ci-Cô alkyl.
- 4. The compound of claim 1, or a pharmaceutically acceptable sait or solvaté thereof, wherein R1 -C(O)R, wherein R is is methyl, ethyl, propyl, or isopropyl.
- 5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable sait or solvaté thereof, wherein R2 is Cj-Cô alkyl, C3-C6 cycloalkyl, or C3-C6 cycloalkylmethyl.
- 6. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable sait or solvaté thereof, wherein R2 is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, or cyclopentylmethyl.
- 7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable sait or solvaté thereof, wherein R3 is Ci-Cg alkyl or C3-C6 cycloalkyl.
- 8. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable sait or solvaté thereof, wherein R3 is methyl, ethyl, propyl, isopropyl, or cyclopropyl.
- 9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable sait or solvaté thereof, wherein R4 is located at the 7-position of the indazole ring, characterized by formula la:(la)
- 10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable sait or solvaté thereof, wherein R4 is hydrogen or halogen.
- 11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable sait or solvaté thereof, wherein R5 is hydrogen or fluoro.
- 12. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable sait or solvaté thereof, wherein R is hydrogen or -C(O)R, wherein R is methyl or ethyl; R is isopropyl, cyclopropyl, cyclopropylmethyl, or cyclopentyl; R3 is methyl or ethyl; R4 is hydrogen or fluoro; and R5 is hydrogen or fluoro.
- 13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable sait or solvaté thereof, selected from the group consisting of:(le) (Id)and r2 r3 .(le)
- 14. The compound of claim 13, wherein R1 is hydrogen or CH3C(O)-; R2 is isopropyl; and R3 is methyl.
- 15. The compound of claim 1, or a pharmaceutically acceptable sait or solvaté thereof, selected from the list of Table 1.
- 16. A pharmaceutical composition comprising a compound of any one of claims 1 to 15, or a pharmaceutically acceptable sait or solvaté thereof, and one or more pharmaceutically acceptable adjuvants, diluents, and/or carriers.
- 17. Use of a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable sait or solvaté thereof, or a composition of claim 16, in the manufacture of a médicament for treatment of a disease or disorder associated with a CDK activity, wherein the CDK is CDK4, CDK6, or a combination thereof.
- 18. The use of claim 17 , wherein said disease or disorder is selected from the group consisting of colorectal cancer, breast cancer, lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantel cell lymphoma (MCL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and inflammation-related diseases and conditions.
- 19. A method of preparing a compound of formula (I), comprising a step of coupling intermediate E with intermediate G:(Mor I) wherein Rp is a protecting group, or the same as R1 when R1 is not hydrogen;wherein when Rp is a protecting group, the method further comprises removal of Rp through base and/or acid mediated hydrolysis to form the compound of formula (laa):5 and reaction of the compound (laa) with an acylating agent R’X4 to form (I), whereinR1 is RC(O)- or ROC(O)-, and X4 is Cl or Br:(laa) (I) and R, R', and R2 through R5 are each independently defined as in any one of claims 110 to 15, andX3isCl, Br, orl.
Publications (1)
Publication Number | Publication Date |
---|---|
OA19873A true OA19873A (en) | 2021-06-23 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019211491B2 (en) | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | |
AU2015292425B2 (en) | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | |
TWI704151B (en) | Erk inhibitors | |
JP6876833B2 (en) | FGFR inhibitors and their use | |
KR102072869B1 (en) | Quinolines as fgfr kinase modulators | |
EP2646432B1 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
TWI710554B (en) | A novel benzimidazole compound and the medical use thereof | |
KR20200020607A (en) | Isoindolin-1-one derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
KR20200110250A (en) | Heteroaryl derivatives, and pharmaceutical composition comprising the same | |
KR102440296B1 (en) | Pyrazole substituted pyrimidine derivative, optical isomer thereof, or pharmaceutically acceptable salts thereof, and composition comprising its same for preventing or treating of cancer | |
AU2018301837A1 (en) | Tam kinase inhibitors | |
OA19873A (en) | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof. | |
CA3188077A1 (en) | Egfr inhibitor, preparation method therefor and application thereof | |
OA18720A (en) | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof. | |
JP2024515204A (en) | Heteroaryl derivative compounds and uses thereof | |
OA18657A (en) | Substituted 2-anilinopyrimidine derivatives as EGFR modulators. |